Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery
Status: | Withdrawn |
---|---|
Conditions: | Infectious Disease, Hospital |
Therapuetic Areas: | Immunology / Infectious Diseases, Other |
Healthy: | No |
Age Range: | Any |
Updated: | 2/1/2017 |
Start Date: | August 2009 |
End Date: | December 2010 |
Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery (TOPS-MRSA)
The investigators anticipate that utilization of retapamulin preoperatively will eliminate
MRSA colonization among patients who are colonized in their nares.
MRSA colonization among patients who are colonized in their nares.
Enhanced characterization of MRSA strains carried by patients and their eradication prior to
surgery will significantly reduce healthcare costs to the VA by reducing the number of MRSA
positive patients who need to be isolated and or closely monitored, and allow healthcare
providers to better predict the patient's requirements. In addition, the application of
molecular methods will facilitate faster tracking of MRSA postoperative infections.
surgery will significantly reduce healthcare costs to the VA by reducing the number of MRSA
positive patients who need to be isolated and or closely monitored, and allow healthcare
providers to better predict the patient's requirements. In addition, the application of
molecular methods will facilitate faster tracking of MRSA postoperative infections.
Inclusion Criteria:
- Patients who are admitted for an orthopedic surgical procedure
- All patients will be screened and admitted to the study prior to surgery regardless
of eventual culture results for MRSA
Exclusion Criteria:
- Pregnancy
- Serious systemic illness due to renal, cardiac or hepatic disease
- Inability to complete follow-up assessments
- Allergy or intolerance to retapamulin
- BMI > 30
- Uncontrolled diabetes, severe anemia, thrombocytopenia or an underlying hematopoietic
disorder or malignancy
- Patients with serious life-threatening illnesses and those with terminal illness not
expected to survive for two years or more will not be enrolled
- Antibiotics administered during the course of the study will be recorded (name, dose
and dates)
We found this trial at
1
site
Click here to add this to my saved trials